I-Corps: Automated, noninvasive critical congenital heart disease (CCHD) screening algorithm/software

美国每年有近400万婴儿出生。所有美国新生儿，以及大多数国际新生儿，都要用脉搏血氧仪进行基于血氧饱和度（SpO2）的重症先天性心脏缺陷（CCHD）筛查。然而，在美国，这种筛查每年仍会漏掉数百名患有危及生命的心脏缺陷的婴儿。拟议的NeoPOSE技术可以防止因婴儿心脏缺陷的晚期发现而导致的死亡。此外，它的无创方法和自动解释使其易于使用，减少与CCHD筛查相关的护理时间。美国大多数州（80%）要求向公共卫生部门报告CCHD筛查数据。大多数医疗机构手动提交数据，这是一项劳动密集型工作，而且容易出错。即使是那些具有自动报告功能的企业，也存在劳动密集型的数据管理困难。NeoPOSE将简化数据传输过程，同时提高其准确性，从而减少与数据管理相关的人工劳动，并提供更可靠的数据，以指导未来的CCHD筛查研究和质量改进。这个I-Corps项目探索无创血流测量技术的商业潜力，以改善对严重先天性心脏缺陷（CCHD）的及时检测。在目前的形式下，血氧饱和度（SpO2）血流量测量不能在临床上用于此目的。提出的NeoPOSE技术可以随时获得尚未使用的无创脉搏血氧仪数据，并使其具有临床相关性。除了CCHD的检测外，该技术还可用于许多其他具有异常血流的医学疾病（即动脉粥样硬化或血管移植监测）。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

There are nearly 4 million babies born in the US every year. All US newborns, and most internationally, undergo oxygen saturation (SpO2) based Critical Congenital Heart Defects (CCHD) screening with pulse oximeters. However, this screening still misses hundreds of babies with life-threatening heart defects in the US every year. The proposed NeoPOSE technology could prevent deaths associated with late detection of heart defects in babies. Moreover, its noninvasive approach and automated interpretation make it easy to use to reduce nursing time associated with CCHD screening. Most US states (80%) require reporting of the CCHD screening data to public health departments. Most health care facilities submit data manually, which is labor intensive and error prone. Even those with automated reporting have data management difficulties that are labor intensive. NeoPOSE will ease the data transmission process while improving its accuracy, thus decreasing manual labor associated with data management and also providing more reliable data to guide future CCHD screening research and quality improvements. This I-Corps project explores the commercial potential of noninvasive blood flow measurement technology for improved timely detection of Critical Congenital Heart Defects (CCHD). In their current form, oxygen saturation (SpO2) blood flow measurements cannot be used clinically for this purpose. The proposed NeoPOSE technology takes readily available, yet unused, noninvasive pulse oximetry data and makes them clinically relevant. In addition to detection of CCHD, the proposed technology may be helpful for a number of other medical diseases with abnormal blood flow (i.e. atherosclerosis or blood vessel graft monitoring).This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.